Exhibit 5.1
VISCHER Ltd
Basel
Aeschenvorstadt 4
CH-4010 Basel
Switzerland
Phone +41 58 211 33 00
Fax +41 58 211 33 10
Zurich
Schützengasse 1
CH-8021 Zurich
Switzerland
Phone +41 58 211 34 00
Fax +41 58 211 34 10
Civil Law Notaries in Basel-City
CRISPR Therapeutics AG
Baarerstrasse 14
6300 Zug
Basel, September 20, 2018
CRISPR Therapeutics AG – Registration Statement on FormS-3
Dear Sir or Madam,
We have acted as Swiss counsel to CRISPR Therapeutics AG (the “Company”), a company incorporated under the laws of the Switzerland, in connection with the Company’s registration statement on FormS-3 as filed with the U.S. Securities and Exchange Commission (the “Commission”), as amended or supplemented (the “Registration Statement”), with respect to the registration under the U.S. Securities Act of 1933, as amended (the “Securities Act”), and the related prospectus covering the Shelf Securities dated September 19, 2018 in the form first used to confirm sales of the offered securities (the “Prospectus”) supplemented by the prospectus supplement (the “Supplement”) specifically relating to the offer and sale of 4,742,104 new ordinary shares of the Company (the “NewShares”). The New Shares will be created through the issuing of 4,742,104 new ordinary shares by the Company pursuant to a capital increase under Swiss Law.
This opinion is confined to and given on the basis of the laws of Switzerland in force at the date hereof and as currently applied by Swiss courts. In the absence of statutory or established case law, we base our opinion on our independent professional judgement.
This opinion is also confined to the matters stated herein and is not to be read as extending, by implication or otherwise, to any other matter.
For the purpose of giving this opinion, We have examined originals or copies, certified or otherwise identified to our satisfaction, of (i) the Registration Statement, (ii) the Prospectus, (iii) the Supplement, (iv) a copy of the coordinated articles of association of the Company as at May 30, 2018 and